UCB (UCBJF) PensionAndRetirementBenefit : $239 Mil (As of Dec. 2024)

View and export this data going back to 2009. Start your Free Trial

What is UCB PensionAndRetirementBenefit?

UCB's PensionAndRetirementBenefit for the quarter that ended in Dec. 2024 was $239 Mil.

UCB's quarterly PensionAndRetirementBenefit increased from Dec. 2023 ($248 Mil) to Jun. 2024 ($278 Mil) but then declined from Jun. 2024 ($278 Mil) to Dec. 2024 ($239 Mil).

UCB's annual PensionAndRetirementBenefit increased from Dec. 2022 ($172 Mil) to Dec. 2023 ($248 Mil) but then declined from Dec. 2023 ($248 Mil) to Dec. 2024 ($239 Mil).

UCB PensionAndRetirementBenefit Historical Data

The historical data trend for UCB's PensionAndRetirementBenefit can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

UCB PensionAndRetirementBenefit Chart

UCB Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

PensionAndRetirementBenefit

Get a 7-Day Free Trial

489.05

355.93

171.61

247.55

238.74

UCB Semi-Annual Data
	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
PensionAndRetirementBenefit	Get a 7-Day Free Trial															171.61	214.52	247.55	277.72	238.74

UCB PensionAndRetirementBenefit Calculation

PensionAndRetirementBenefit is the carrying amount as of the balance sheet date of the portion of the obligations recognized for the various benefits provided to former or inactive employees, their beneficiaries, and covered dependents after employment but before retirement.

UCB Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » UCB SA (OTCPK:UCBJF) » Definitions » PensionAndRetirementBenefit

Comparable Companies

Traded in Other Exchanges

UCBJY:USA UCBb:UK 0NZT:UK UNC:Germany UCB:Belgium UCB:Austria

Address

Allee de la Recherche, 60, Brussels, BEL, B-1070

Website

https://www.ucb.com

UCB is a Belgium-based biopharma firm focused on the development of novel therapies for the treatment of central nervous system and immunologic diseases. Historically, revenue was derived from allergy medicine Zyrtec and epilepsy drug Keppra, which have both lost patent protection. The firm's key products are Cimzia (immunology), Vimpat (epilepsy), Neupro (Parkinson's disease and restless leg syndrome), Briviact (epilepsy), Bimzelx (psoriasis), Evenity (osteoporosis), Nayzilam (cluster seizures), and Fintepla (Dravet Syndrome and Lennox-Gastaut Syndrome).